Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

References

• Smith T, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29:319-24
   Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
   PubMed Web of Science ®Google Scholar
• Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-71
   PubMedGoogle Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10:715-24
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402-7
   PubMed Web of Science ®Google Scholar
• Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003;9:15-21
   PubMedGoogle Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-76
   PubMed Web of Science ®Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der HB, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-50
   PubMed Web of Science ®Google Scholar
• Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1503-8
   PubMed Web of Science ®Google Scholar
• Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-8
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-11
   PubMed Web of Science ®Google Scholar
• Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
   PubMed Web of Science ®Google Scholar
• Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-52
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277-83
   PubMed Web of Science ®Google Scholar
• US Department of Labor. Bureau of Labor Statistics. 2006. Available at: http://www.bls.gov/cpi/home.htm#overview [Last accessed February 23, 2007]
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price. 2006 ASP Drug Pricing Files. 2007. Available at: http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp [Last accessed March 18, 2008]
   Google Scholar
• Current procedural terminology (CPT) 2006. Chicago, IL: American Medical Association. CPT 99211, CPT 90772
   Google Scholar
• Centers for Medicare & Medicaid Services. 2006 Medicare physician fee schedule. 2006. Available at: http://www.cms.hhs.gov/PFSlookup/[Last accessed March 18, 2008]
   Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• 2006 DRG Expert: a comprehensive reference to the DRG classification system. Volume 21. Ingenix, Inc., Salt Lake City, UT 84120
   Google Scholar
• Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-60
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer. J Clin Oncol 2006;24:2991-7
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Glass A, et al. Cost of chemotherapy-related febrile neutropenia. J Clin Oncol 2006;24:(abstract 6068)
   Web of Science ®Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-34
   PubMed Web of Science ®Google Scholar
• Chamilos G, Bamias A, Efstathiou E, et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005;103:2629-35
   PubMed Web of Science ®Google Scholar
• Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004;12:555-60
   PubMed Web of Science ®Google Scholar
• Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47-56
   PubMedGoogle Scholar
• Uyl-de Groot CA, Hagenbeek A, Verdonck LF, et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995;16:463-70
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001;19:1091-102
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998;9:899-907
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1
   PubMed Web of Science ®Google Scholar
• Pettengell R, Bosly A, Szucs TD, et al. INC-EU Prospective observational European neutropenia study: preliminary Hodgkin and non-Hodgkin lymphoma results. Abstract 284. 11th Congress of the European Hematology Association, June 15--18, 2006, Amsterdam, The Netherlands. 2006
   Google Scholar
• Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008;87:429-30
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. 2005. Available at: www.seer.cancer.gov [Last accessed November 16, 2007]
   Google Scholar
• National Vital Statistics Reports, Vol. 53, No. 6, November 10, 2004, Table 3. Life table for females: United States. Centers for Disease Control and Prevention, National Vital Statistics System. 2002. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf [Last accessed February 23, 2007]
   Google Scholar
• United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Compressed Mortality File (CMF) compiled from CMF 1999-2002, Series 20, No. 2H 2004 on CDC WONDER On-line Database
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87
   PubMed Web of Science ®Google Scholar
• Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves -- facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15
   PubMed Web of Science ®Google Scholar
• Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York: Oxford University Press, 2005
   Google Scholar
• Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000;19:92-109
   PubMed Web of Science ®Google Scholar
• Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/TA137guidance.pdf [Last accessed October 29, 2008]
   Google Scholar
• Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9
   PubMed Web of Science ®Google Scholar
• Zbrozek AS, Cantor SB, Cardenas MP, et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994;51:1555-63
   PubMedGoogle Scholar
• Lister-Sharp D, McDonagh MS, Khan KS, et al. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess 2000;4:1-113
   Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-9
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2008;Jul 31 [Epub ahead of print]
   Web of Science ®Google Scholar
• Girmenia C, Russo E, Carmosino I, et al. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 2007;86:263-70
   PubMed Web of Science ®Google Scholar
• Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103:1644-51
   PubMed Web of Science ®Google Scholar